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Abstract
Background: Travelers are at risk of contracting malaria when moving to endemic areas. Yet, despite effective malaria chemoprophylaxis, imported cases of malaria still occur 
worldwide. Indeed, some studies have shown a varied adherence level; consequently, a traveler care gap could occur. 
Methods: A prospective cohort study was carried out in 2017 to evaluate the rate of malaria chemoprophylaxis adherence among Spanish travelers. 
Results: A post-travel questionnaire was completed by 402 travelers to malaria endemic areas that were prescribed chemoprophylaxis: 67 (16.7%) did not take any dose 
of chemoprophylaxis and 41 (10.2%) had not even carried it while travelling abroad. The adherence of chemoprophylaxis was 68,7% of travelers, being statistically different 
according to travel duration, onset of adverse events and type of drug prescribed. The non-adherent travelers reported not continuing with administration mainly because of 
forgetfulness, fear of side effects and low perceived risk because itinerary changes.
Regarding the onset of the medication’s secondary adverse events, one in three (35.2%) reported at least one, being more frequent among patients that took mefloquine than 
atovaquone-proguanil (p=0.01). The main adverse events reported by chemoprophylaxis users were gastrointestinal or sleeping disorders.
Conclusions: The suboptimal compliance of chemoprophylaxis is a major lost opportunity to achieve malaria prevention, so it is an important contributor to the traveler care gap. 
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INTRODUCTION 
According to the World Health Organization (WHO) World 
Malaria Report of 2017, there were about 216 million cases of 
malaria estimated in 2016, with less than half a million of deaths 
[1]. As is known, travelers represent a selected population at risk 
when moving to endemic zones, such as large areas of Africa, 
Latin America, Asia (including South Asia, Southeast Asia, and the 
Middle East), and the South Pacific [2]. 
The care taken by travelers to avoid malaria could present 
some gaps which may be explained by sub-optimal patient access 
to a travel clinic; non-prescription of proven chemoprophylaxis 
when needed; poor adherence to chemoprophylaxis, and 
inadequate diagnosis of the presence of malaria overseas or in 
developed countries [3]. Adherence to prevention strategies such 
as avoiding mosquito bites and to chemoprophylaxis are keys 
components of success in preventing malaria in travelers [4], 
as well as to reduce imported malaria infections in countries of 
origin and transit [5]. Nevertheless, compliance with protective 
measures amongst travelers is still sub-optimal [6,7], embodying 
a substantial, well-recognized global public health problem 
sustained by an important avoidable rate of malaria among 
people travelling abroad. This is also associated with mortality 
and increased health-care expenses [8-11]. Such a poor level of 
adherence to malaria chemoprophylaxis may be influenced by 
several factors: lack of knowledge about the disease, low risk 
perception, onset of secondary adverse effects, the long duration 
of treatment or the travel characteristics. These could differ 
markedly according to the traveler’s country of origin [12].
Malaria chemoprophylaxis adherence demands perseverance 
and is a mutually agreed component in the traveler-provider 
covenant, following professional indication, recommendation 
and prescription of evidence-based therapy. In contemporary 
traveler-centered care, a concordant understanding of indication, 
prescription and consent of the risks and benefits of possible 
malaria chemoprophylaxis are highly desired outcomes of the 
bilateral discussion between professionals and travelers as they 
seek a mutually determined malaria prevention strategy. In the 
short term, the compliance components of adherence refer to 
travelers’ understanding and commitment to specific indication, 
or prescription requirements [13].
Some studies about malaria prevention were conducted in 
the airports and consisted of a questionnaire with no subsequent 
follow-up of any type. One of these studies conducted in our 
region [14] showed that 34.8% of travelers carried antimalarials, 
but no idea about adherence.
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The adherence of malaria chemoprophylaxis could vary 
across the evidence [12], also depending on adherence definition. 
Much of the literature defines malaria chemoprophylaxis 
adherence in terms of whether all pills were taken as prescribed 
(63-89%) [15-19]. Adherence to chemoprophylaxis (CP) was 
defined in previous studies as travelers who took at least 75% 
of their prescribed pills during their stay; and non-adherence to 
those who took less than 75% [16,20].
Although recommendations for the length of 
chemoprophylaxis course have been defined, for some medication 
there is contention over what proportion of a recommended 
chemoprophylaxis course is necessary to provide detection [21]. 
The main reasons for non-adherence include forgetfulness, 
fear of side effects, low perceived risk, even related to unseen 
flying mosquitoes [20]; or high cost of provider visits and 
chemoprophylaxis, and cultural barriers [22].
In this research field, despite the presence of some information 
available addressing travelers’ adherence to chemoprophylaxis, 
an in-depth knowledge of this issue is of special relevance, in 
particular regarding changes over time. Furthermore, current 
literature on this subject is still lacking in our region. 
Therefore, the goals of this prospective cohort study were to 
assess the level of adherence towards chemoprophylaxis among 
travelers, highlighting the main predictors. 
METHODS 
Study design and setting
Travelers who consecutively attended a travel clinic and were 
travelling to countries with endemic malaria were invited to 
participate in a prospective cohort study about their adherence 
to malaria chemoprophylaxis. 
Travelers who had completed their journey after the 31st of 
December 2017 were excluded from the study. The information 
was gathered by two questionnaires: one that was completed 
face-to-face prior to the trip and during the medical visit (baseline 
questionnaire) and another that was completed by phone or 
email from 3 to 4 weeks after the expected return date (post-
travel questionnaire).
The study was conducted at the Travel Health Clinic at the 
Hospital Universitari de Bellvitge (HUB), in Barcelona, Spain.
Participants
Travelers seeking medical advice at the travel clinic, between 
January 2017 and December 2017, before travelling to areas with 
endemic malaria, who agreed to participate in the study and to be 
contacted after their trip, were included. Exclusion criteria were 
as follows: aged younger than 3 years, people not travelling to 
areas with endemic malaria or finally not travelling anywhere, 
patients with contraindications to the chemoprophylaxis (in 
particular people with severe renal impairment [creatinine 
clearance <30 mL/min], pregnant women, women breastfeeding 
infants weighing <5kg, or a history of hypersensitivity to 
antimalarial drugs), patients that receive chemoprophylaxis and 
stand-by emergency treatment for the same travel, and patients 
refusing chemoprophylaxis prescription or not willing to 
participate in the study. Those individuals included were asked 
to provide their phone numbers and email addresses, for the 
follow-up purpose of this research. Involvement was voluntary, 
and no incentives were offered to complete it. Travelers were 
informed that all information gathered would be anonymous 
and that confidentiality would be maintained by omitting any 
personal identifying information from the analysis. A written 
informed consent was obtained, and the Institutional Review 
Board of HUB granted approval for carrying out this research.
Participants were provided with information about malaria 
and its preventive measures; they were also instructed in how/
when to self-administer chemoprophylaxis. Depending on 
the travelers’ characteristics, type of journey and a bilateral 
decision between traveler and provider [23], the participants 
were prescribed atovaquone 250 mg and proguanil 100 mg, 
mefloquine 250 mg, or doxycycline 100 mg. Implementation of 
other interventions to avoid mosquito bites, such as a mosquito 
net, repellent and appropriate clothes, were also recommended. 
Research instruments and outcomes measures
For the purpose of this survey-based prospective cohort 
study, two structured administered questionnaires were 
designed, as baseline and post-travel surveys. 
The pre-travel questionnaire, completed face-to-face during 
the pre-travel medical visit, assessed the socio-demographic 
characteristics of the participants, which were collected 
as follows: age, gender, self-reported medical history, and 
information about travel, such as destination and duration. The 
previous use of anti-malarial drugs and if participants had ever 
experienced adverse effects were also investigated. 
The post-travel information was gathered by an online 
questionnaire, which was delivered to all participants via 
professional online survey software (Google® Forms), between 
3 and 4 weeks after the expected returns. All travelers received 
an email inviting them to complete the survey, accessible via an 
embedded URL link. Non-respondents received a reminder 2 
weeks later. A clear preliminary statement provided information 
to the cohort about the study and instructions, and also allowed 
participants to confirm their own informed consent to carrying 
out the survey. The second research instrument, designed for 
capturing information about participants’ compliance with and 
behaviors towards chemoprophylaxis, comprised a question 
whether travelers had gone to the pharmacy to buy the CP and 
if they have carried anti-malarial medication during their travel 
abroad. According to National Health Service CP prescription is a 
part of it, so once the traveler is attended in our Travel Clinic he 
has the prescription to buy the CP and the maximum cost to pay 
for it is the 40% of its price. On the other hand, we have verified 
if patients had gone to the pharmacy to collect it by informatics 
traceability of prescription. If participants answered “Yes, I 
have carried my anti-malarial medication”, they were invited 
to provide information regarding self-administration of the 
prescribed prophylaxis. This included how long patients took the 
drugs, when they started and finished, if any adverse effects were 
experienced, and if chemoprophylaxis was suspended before the 
indicated period and why (cost, disbelief in efficacy, concern of 
side effects, forgetfulness, or misunderstanding about how and 
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when to take it). If participants answered “No, I have not carried 
my anti-malarial medication”, they were invited to provide 
information regarding main reasons to it.
Both questionnaires were pre-tested and piloted with a 
convenience sample of 25 travelers similar to the study population, 
who were asked for their feedback of surveys acceptability in 
terms of length, clarity, and question format. Based on these 
suggestions, some minor revisions included changes to the 
questionnaire items wording and format. After collection, data 
were automatically stored in an electronic spreadsheet and were 
cleaned in order to reduce the risk of measurement error. 
Statistical analysis 
The statistical analysis was carried out using Stata version 13 
[24] statistical software and consisted of two phases: descriptive 
and inferential analysis according to normal distribution studied 
by the Kolmogorov-Smirnov test. 
Chi-square (χ2) or Fisher’s exact tests were used to assess 
differences between categories when needed; the Mann-Whitney 
U test was used to assess differences between independent 
means between participants who complied or did not comply. 
Univariate analyses were also conducted to determinate the 
effects on the travelers’ suspension of chemoprophylaxis of 
the following independent variables: gender, age, prescribed 
chemoprophylaxis drugs, duration of travel, and the onset 
of adverse effects. Subsequently, these independent and 
uncorrelated variables were included in a mutually adjusted 
multivariate logistic regression model. Results were reported as 
odds ratios (ORs) and 95% confidence intervals (CIs). 
All inferential tests were performed with significant statistical 
levels for p-values equal to or less than 0.05.
RESULTS 
Of 1,025 travelers who attended the Travel Medicine Clinic of 
the HUB from January to December 2017, there were 869 (84,8%) 
that accepted to participate, finally travelled to endemic malaria 
areas and were prescribed only chemoprophylaxis. In fact, 
there were 32 (3.1%) travelers did not accept to participate, 68 
(6.9%) did not go to malaria endemic areas, and 56 (5.6%) were 
prescribed with chemoprophylaxis and Stand-By Emergency 
Treatment (SBET). Selected characteristics of the overall study 
participants are presented in Table 1 and a flow-chart of the 
number of participants in the study was designed in Figure 1. 
Slightly more than half of the participants were female (n=494, 
56.5%) and the mean age was 35.6 years (SD 13.0). There were 
10.6% (n=92) of participants who reported pre-existing medical 
conditions and 16.7% (n=145) also declared regular medication 
consumption, with contraceptive (5.8%), antihypertensive 
(1.9%) and thyroid hormones (1.3%) as the most frequently used 
drugs. 
Less than a fifth of the sample (n=155, 17.8%) had previously 
used antimalarial chemoprophylaxis in previous travels and 42 
(27.1%) of these also reported adverse effects: most complained 
of symptoms that were gastrointestinal (mainly nausea and 
gastric pain or discomfort) and sleep disorders.
Regarding travel information, the vast majority of the study 
population travelled for a mean of 21.5 (SD 15.3) days to Africa 
(n=634, 73.0%), with Kenya (n=162, 18.6%), Senegal (n=93, 
11.3%), and Tanzania (n=104, 12.0%) as the most popular 
destinations. Another group of patients (n=156, 17.9%) travelled 
to Asia, mainly to the south-eastern part of the continent (with 
Indonesia as the most visited destination, n=80, 9.2%). The 
remaining 79 subjects (9.1%) had planned to go to Central and 
South America.
Of the recruited participants, 402 completed the post-travel 
online survey for an overall response rate of 46.3%. The exact 
number of pills prescribed was available for 393 (97.88%) of 402 
participants. 
Regarding travelers that were prescribed CP alone, without 
SBET, 83.3% of them (n=335) took at least one dose being 
accurate its intake in 68.7% (n=230). However, 31.3% (n=105) 
of travelers prescribed CP did not take at least 75% of medication 
prescribed and were defined as non-adherent. 



































Duration of travel (in days)° 21.6 ± 14.9 (5-185) 20.9 ± 14.3 (5-96) 21.6 ± 15.1 (5-185) 0.02















° Variables summarized by mean ± standard deviation (SD), and range.
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1025 travellers accessed the HUB Travel 
Medicine Clinic and travelled to malaria 
endemic areas in the study period
869 (84.8%) accepted to participate in the 
study and were prescribed with CP
402 (46.2%) completed the online post-travel 
survey
467 (53.7%) non-respondents
67 (16.7%) did not use CP 335 (83.3%) used CP
105 (31.3%) suspended the 
prophylaxis
86 because of AEs onset 
16 forgot continuing CP 
3 changed travel route
Figure 1 Flow-chart of number of participants in the study.
No statistically significant differences were found between 
the adherent and non- adherent groups’ characteristics, except 
for the duration of travel with the adherent participants travelling 
for less time than the non- adherent population (Table 2).
The non-adherent travelers to CP (n=105) reported not 
continuing with administration mainly because of the onset 
of adverse effects, concern about these effects and disbelief in 
efficacy (n=86, 81,9%); or because they forgot to keep taking the 
medication after their return (i.e., forgetfulness) (n=16, 15,2%); 
or because they changed the route of the voyage (i.e., the concern 
of adequate malaria chemoprophylaxis prescription according 
to final destination) (n=3, 2,8%). The odds of non-adherence 
were higher in the group prescribed with mefloquine compared 
with participants who were prescribed with other regimens 
(OR=3.13; 95% IC 1.09 - 10.12). In the adjusted multivariate 
analysis, the risk of non-adherence was 3 times higher in the 
mefloquine group than the other groups, if the traveler presented 
at least one adverse effect; in addition, there was a 3% higher risk 
of discontinuation per day of travel duration, independently of 
age and gender (Table 3).
One in three (35.2%) travelers that took at least one dose 
of CP (n=335) reported any adverse events, being significantly 
higher among patients that took mefloquine than atovaquone-
proguanil (p=0.01). On the other hand, among subjects who 
reported a drug-related adverse event, the mean number of 
adverse event (±SD) per subject was 1.2±0.7 for subjects while 
receiving atovaquone-proguanil and 2.1+-1.9 for subjects 
while receiving mefloquine (p<0.05). The main adverse events 
reported by chemoprophylaxis users were gastrointestinal 
or sleeping disorders. Sleeping disorders were found more 



































Duration of travel (in days)° 20.5 ± 14.6 (5-93) 19.5 ± 12.8 (5-95) 26.1 ± 22.2 (5-93) 0.01















° Variables summarized by mean ± standard deviation (SD), and range.
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frequently in travelers prescribed with mefloquine (26.0% vs. 
7.7%, p<0.05). Table 4 shows the adverse events reported by 
travelers, according to the prescribed prophylaxis. Doxycycline 
was indicated and taken by 4 travelers who did not complain any 
adverse events. Neither hospitalization nor emergency visits due 
to adverse events were reported. 
To the best of our knowledge, no cases of malaria were 
observed in the sample. 
DISCUSSION 
First, it is worth emphasizing that, predictably, the 73.7% of 
enrolled subjects, for whom chemoprophylaxis was indicated, 
were travelling to African countries, which carry 90% of all cases 
of malaria and represent a relevant part of the global disease 
burden [1].
This survey-based prospective cohort study yielded 
interesting findings regarding the adherence to malaria 
chemoprophylaxis amongst travelers and the data from this 
research indicated that the current state of their compliance 
with protective measures is suboptimal. We found 68.7% of 
travelers took at least 75% of their chemoprophylaxis prescribed 
compared to 84% in a Dutch study [16] or 89% in an American 
study [20].
Only 7.3% of travelers who were completely in compliance 
with chemoprophylaxis. Our data also substantiates a low level of 
awareness and perception of malaria risk among travelers [12].
Analysis of the predictors of being more likely to lead to 
chemoprophylaxis non adherence showed that there was a 
significant difference in the level of discontinuation according to 
the type of prescribed drug, duration of travel, and development 
of one or more adverse effects independently of age and gender. 
The associations found may be explained by the fact that 
the longer the duration of travel, the longer the period when 
chemoprophylaxis is indicated, and hence the most factors 
which could negatively influence adherence. Indeed, specific in-
depth studies have analyzed this aspect, highlighting problems 
related to chemoprophylaxis continuation in long-term travelers, 
Table 3: Univariate and multivariate analysis indicating associations between variables and chemoprophylaxis (CP) non-adherence.
Crude Adjusted*





0.83 0.44 - 1.61
1
0.86 0.43 - 1.66
Age (in years) 0.98 0.97 - 1.01 0.98 0.96 - 1.01
Prescribed CP drugs
Atovaquone/proguanil Mefloquine 13.13 1.09 - 10.12
1
3.69 1.12 - 12.54
Duration of travel (in days) 1.02 1.00 - 1.04 1.03 1.02 - 1.05
Onset of adverse effects
No adverse effects
At least 1 or more
1
3.41 1.79 - 6.53
1
3.91 1.87 - 7.83
CP, antimalarial chemoprophylaxis; OR, odds ratio; 95% CI, 95% confidence interval 
*Adjusted by gender, age, prescribed chemoprophylaxis drugs, duration of travel, and onset of adverse effects.
Table 4: Adverse events reported by chemoprophylaxis users (n=335)*°.











   Nausea 17 (5.4%) 1 (4.3%)
   Vomiting 6 (1.9%) 0 (0%)
   Gastric pain or discomfort 49 (15.7%) 3 (13.0%)
   Diarrhoea 5 (1.6%) 1 (4.3%)







Others 5 (1.6%) 0 (0%)
° Interviewees could choose more than one item 
*Numbers of items may not add up to the total study population because of missing values.
**Among subjects who reported a drug-related adverse event, the mean number of adverse event (±SD) per subject 
was 1.2±0.7 for subjects while receiving atovaquone-proguanil and 2.1±1.9 for subjects while receiving mefloquine.
***Sleeping disorder comprises insomnia, strange or vivid dreams
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including the possibility of discussing other measures in case of 
long stays (e.g. SBET, when also indicated) [25-28].
The frequency of adverse events in the chemoprophylaxis 
in the present study was quite similar to the frequency in 
previous studies [29]. Regarding the onset of adverse events, 
participants complained of the usual symptoms reported 
by chemoprophylaxis users, being more frequent among 
mefloquine users. The difference was especially pronounced for 
sleeping disorders in mefloquine users. Indeed, in the literature, 
it is well defined that this antimalarial drug has the highest 
proportion of neuropsychiatric adverse effects, especially that of 
insomnia. [29,30] On the other hand we have observed a larger 
gastrointestinal number of events in both chemoprophylactic 
courses (atovaquone-proguanil and mefloquine) than in previous 
studies that ranged between 16 and 19% [29]. Moreover, the fact 
of experiencing adverse effects may itself prompt users to stop 
the prophylaxis, as shown in the fully adjusted logistic regression 
model. 
An interesting finding is that sixteen interviewees forgot to 
keep taking the chemoprophylaxis during the prescribed time. 
This behavior may result in part from a lack of knowledge about 
malaria and the possibility of its onset after returning home. This 
is because the disease’s incubation period is 7 days or longer, 
depending on many factors, particularly which Plasmodium 
species is responsible for the infection [31-33]. Therefore, the 
idea of leaving countries and areas at risk of malaria transmission 
may falsely reassure travelers and during pre-travel consultation 
it is important to inform patients about malaria itself and to 
stress the necessity of using an antimalarial for all the prescribed 
period. 
Regarding chemoprophylaxis length some recall bias could 
occur as we could not verify with the patient how many tablets do 
they still have at home. Furthermore, other potential limitations 
might affect the value of this research. The first is the cohort 
design of the study that does not make it possible to establish 
causal effects. In addition, participants were not allocated blindly 
and randomly to the study: the possibility that the association 
found may be explained by other confounders should be taken 
into account. However, cohort studies use broader inclusion 
criteria and less exclusion criteria compared to randomized 
studies, making results more generalizable to clinical practice. 
Furthermore, a possible non-response bias must be considered 
due to a rather moderate response rate, even though the absence 
of relevant differences between responders and non-responders 
allowed us assume an equal distribution of participants’ 
characteristics, lessening this limitation. Finally, the study 
enrolled only travelers seeking pre-travel advice in our unit and 
does not include subject seeking it elsewhere or not seeking it 
at all, so this cohort might be inadequate for determining all 
the predictors of CP adherence or might make the sample not 
representative of the whole target population of travelers and 
results not completely applicable to other centers.
Despite these limitations, the strengths of this study were 
that the cohort was properly selected; the study design was 
appropriate and allowed us to meet the temporality criterion for 
causality. Moreover, the methodology of the study was accurate, 
reducing problems of bias.
CONCLUSIONS
In conclusion, this study resulted in providing useful 
information of travelers’ adherence to malaria chemoprophylaxis 
and in fostering further research likely to be useful in global 
public health and for health-policy makers. Indeed, adherence to 
chemoprophylaxis is an important factor of success in preventing 
malaria [4] and its correct implementation should be the key 
message during pre-travel medical visits, particularly when 
factors found likely to be associated with chemoprophylaxis 
misuse are evaluated during consultations. 
Health promotion about malaria prevention at a travel clinic 
needs some expansion to produce substantial health benefits and 
efficacy among travelers. It seems an outstanding opportunity to 
promote the importance of malaria prevention, particularly in 
population at greater risk for the disease [34]. 
KEY ISSUES
- The success of malaria chemoprophylaxis depends mainly 
on travelers’ adherence. 
- A suboptimal level of adherence to malaria chemoprophylaxis 
exists, which is influenced by several factors, such as the 
characteristics of the individual, the travel and the type of 
prescribed antimalarial drug. 
- Onset of drugs’ adverse effects may induce travelers to 
suspend the chemoprophylaxis for malaria.
- The longer the schedule of chemoprophylaxis, the more 
likely is an offset in the dose assumed by travelers. 
- Further research is needed to investigate other predictors of 
travelers’ behavior. 
- Health promotion and malaria prevention concepts need to 
be stressed at travel clinics to foster health benefits and efficacy 
among travelers.
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